- Longeveron (NASDAQ:LGVN) said on Tuesday that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its stem cell therapy laromestrocel as a potential treatment for pediatric dilated cardiomyopathy (DCM).
- The accepted IND application provides for moving directly to a single Phase 2 pivotal registration clinical trial.
- LGVN is +3.1% to $1.33
- Source: Press Release
